# [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2

> **NCT05579184** · PHASE2 · UNKNOWN · sponsor: **FutureChem** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer, mCRPC

## Interventions

- **DRUG:** [177Lu]Ludotadipep

## Key facts

- **NCT ID:** NCT05579184
- **Lead sponsor:** FutureChem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579184, "[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05579184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*